Physiologic Study of Cerebral Perfusion

NCT02744625 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Cerebral Perfusion Pressure
Vasopressor Agents
Shock
Magnetic Resonance Imaging (MRI), Functional

Interventions

DRUG: Higher doses of vasopressor therapy for a MAP of 75 mmHg
DRUG: Lower doses of vasopressor therapy for a MAP of 65 mmHg
DRUG: Propofol for light sedation

Sponsor

Centre de recherche du Centre hospitalier universitaire de Sherbrooke